ES2138565A1 - Uso del interferon alfa 5 en el tratamiento de las haepatopatias virales. - Google Patents

Uso del interferon alfa 5 en el tratamiento de las haepatopatias virales.

Info

Publication number
ES2138565A1
ES2138565A1 ES009801003A ES9801003A ES2138565A1 ES 2138565 A1 ES2138565 A1 ES 2138565A1 ES 009801003 A ES009801003 A ES 009801003A ES 9801003 A ES9801003 A ES 9801003A ES 2138565 A1 ES2138565 A1 ES 2138565A1
Authority
ES
Spain
Prior art keywords
livers
treatment
alpha
sub
type
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES009801003A
Other languages
English (en)
Other versions
ES2138565B1 (es
Inventor
Valtuena Jesus Prieto
Murillo Pilar Civeira
Leoz Esther Larrea
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Instituto Cientifico y Tecnologico de Navarra SA
Original Assignee
Instituto Cientifico y Tecnologico de Navarra SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to ES009801003A priority Critical patent/ES2138565B1/es
Application filed by Instituto Cientifico y Tecnologico de Navarra SA filed Critical Instituto Cientifico y Tecnologico de Navarra SA
Priority to BR9911774-6A priority patent/BR9911774A/pt
Priority to US09/674,445 priority patent/US6995133B1/en
Priority to AU37111/99A priority patent/AU753463B2/en
Priority to AT99919282T priority patent/ATE214941T1/de
Priority to PCT/ES1999/000134 priority patent/WO1999058143A1/es
Priority to EP99919282A priority patent/EP1077068B9/en
Priority to RU2000131172/14A priority patent/RU2209079C2/ru
Priority to DE69901099A priority patent/DE69901099D1/de
Priority to ES99919282T priority patent/ES2174604T3/es
Priority to JP2000547994A priority patent/JP2002514606A/ja
Priority to DK99919282T priority patent/DK1077068T5/da
Priority to PT99919282T priority patent/PT1077068E/pt
Priority to CA2335645A priority patent/CA2335645C/en
Priority to CNB998078662A priority patent/CN1173738C/zh
Priority to DE69901099T priority patent/DE69901099T4/de
Priority to SI9930043T priority patent/SI1077068T1/xx
Priority to SE99919282T priority patent/SE1077068T5/xx
Publication of ES2138565A1 publication Critical patent/ES2138565A1/es
Application granted granted Critical
Publication of ES2138565B1 publication Critical patent/ES2138565B1/es
Priority to US11/212,126 priority patent/US7501392B2/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Steroid Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Uso del interferon alfa-5 en el tratamiento de las hepatopatías virales. La invención describe la síntesis disminuida de IFNa-5 en hígados de pacientes con hepatitis C, frente a hígados de controles sanos. El subtipo de IFN expresado en dichos hígados sanos, correspondió únicamente al subtipo alfa-5, frente a los diferentes subtipos expresados en hígados enfermos. En SEQ ID NO:1 se muestra la secuencia parcial de cADN correspondiente a IFNa 5. Estas diferencias significativas entre los patrones de expresión de unos hígados y otros ponen de manifiesto la importancia del uso de este subtipo de interferon en la fabricación de composiciones útiles en el tratamiento de hepatopatías de origen viral. En la invención se describe pormenorizadamente esta utilización bajo diferentes formas y procedimientos, incluyendo aquellos que utilizan la producción de proteínas recombinantes, a partir de secuencias tipo SEQ ID NO:1.
ES009801003A 1998-05-13 1998-05-13 Uso del interferon alfa 5 en el tratamiento de las hepatopatias viral es. Expired - Lifetime ES2138565B1 (es)

Priority Applications (19)

Application Number Priority Date Filing Date Title
ES009801003A ES2138565B1 (es) 1998-05-13 1998-05-13 Uso del interferon alfa 5 en el tratamiento de las hepatopatias viral es.
DK99919282T DK1077068T5 (da) 1998-05-13 1999-05-13 Anvendelse af interferon alfa 5 i behandlingen af virale hepatopatier
AU37111/99A AU753463B2 (en) 1998-05-13 1999-05-13 Utilization of interferon alpha 5 in the treatment of viral hepatopathies
AT99919282T ATE214941T1 (de) 1998-05-13 1999-05-13 Verwendung von interferon alpha 5 in der behandlung viraler hepatopathien
PCT/ES1999/000134 WO1999058143A1 (es) 1998-05-13 1999-05-13 Uso del interferon alfa 5 en el tratamiento de las hepatopatias virales
EP99919282A EP1077068B9 (en) 1998-05-13 1999-05-13 Utilization of interferon alpha 5 in the treatment of viral hepatopathies
RU2000131172/14A RU2209079C2 (ru) 1998-05-13 1999-05-13 Применение интерферона-альфа 5 в лечении вирусных заболеваний печени
CA2335645A CA2335645C (en) 1998-05-13 1999-05-13 Use of interferon alpha 5 in the treatment of viral liver diseases
US09/674,445 US6995133B1 (en) 1998-05-13 1999-05-13 Utilization of interferon alpha 5 in the treatment of viral hepatopathies
JP2000547994A JP2002514606A (ja) 1998-05-13 1999-05-13 ウィルス性肝疾患の治療へのインターフェロンα５の使用
BR9911774-6A BR9911774A (pt) 1998-05-13 1999-05-13 Uso de interferon alfa 5 no tratamento das hepatopatias virais
ES99919282T ES2174604T3 (es) 1998-05-13 1999-05-13 Utilizacion de interferon alfa 5 en el tratamiento de las hepatopatias de origen viral.
DE69901099A DE69901099D1 (de) 1998-05-13 1999-05-13 Verwendung von interferon alpha 5 in der behandlung viraler hepatopathien
CNB998078662A CN1173738C (zh) 1998-05-13 1999-05-13 干扰素α5在制备治疗病毒性肝脏疾病的组合物中的应用
DE69901099T DE69901099T4 (de) 1998-05-13 1999-05-13 Verwendung von interferon alpha 5 in der behandlung viraler hepatopathien
SI9930043T SI1077068T1 (en) 1998-05-13 1999-05-13 Utilization of interferon alpha 5 in the treatment of viral hepatopathies
SE99919282T SE1077068T5 (sv) 1998-05-13 1999-05-13 Anvaendning av interferon-alfa-5 vid behandling av virus-hepatopatier
PT99919282T PT1077068E (pt) 1998-05-13 1999-05-13 Utilizacao do interferao alfa 5 no tratamento de hepatopatias virais
US11/212,126 US7501392B2 (en) 1998-05-13 2005-08-25 Method of treatment of viral hepatitis C with interferon alpha 5

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES009801003A ES2138565B1 (es) 1998-05-13 1998-05-13 Uso del interferon alfa 5 en el tratamiento de las hepatopatias viral es.

Publications (2)

Publication Number Publication Date
ES2138565A1 true ES2138565A1 (es) 2000-01-01
ES2138565B1 ES2138565B1 (es) 2000-08-16

Family

ID=8303773

Family Applications (2)

Application Number Title Priority Date Filing Date
ES009801003A Expired - Lifetime ES2138565B1 (es) 1998-05-13 1998-05-13 Uso del interferon alfa 5 en el tratamiento de las hepatopatias viral es.
ES99919282T Expired - Lifetime ES2174604T3 (es) 1998-05-13 1999-05-13 Utilizacion de interferon alfa 5 en el tratamiento de las hepatopatias de origen viral.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES99919282T Expired - Lifetime ES2174604T3 (es) 1998-05-13 1999-05-13 Utilizacion de interferon alfa 5 en el tratamiento de las hepatopatias de origen viral.

Country Status (15)

Country Link
US (2) US6995133B1 (es)
EP (1) EP1077068B9 (es)
JP (1) JP2002514606A (es)
CN (1) CN1173738C (es)
AT (1) ATE214941T1 (es)
AU (1) AU753463B2 (es)
BR (1) BR9911774A (es)
CA (1) CA2335645C (es)
DE (2) DE69901099D1 (es)
DK (1) DK1077068T5 (es)
ES (2) ES2138565B1 (es)
PT (1) PT1077068E (es)
RU (1) RU2209079C2 (es)
SE (1) SE1077068T5 (es)
WO (1) WO1999058143A1 (es)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006032711A1 (es) * 2004-08-18 2006-03-30 Instituto Científico Y Tecnológico De Navarra S.A. Uso del factor de crecimiento semejante a la insulina tipo i y de interferón alfa en el tratamiento de una enfermedad hepática crónica, kit y composiciones que los comprenden
ES2303492A1 (es) * 2004-08-18 2008-08-01 Instituto Cientifico Y Tecnologico De Navarra S.A. Uso del factor de crecimiento semejante a la insulina tipo i y de interferon alfa en el tratamiento de una enfermedad hepatica cronica, kit y composiciones que los comprenden.

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110179530A1 (en) * 2001-01-23 2011-07-21 University Of Central Florida Research Foundation, Inc. Pharmaceutical Proteins, Human Therapeutics, Human Serum Albumin Insulin, Native Cholera Toxin B Subunit on Transgenic Plastids
FR2824333B1 (fr) * 2001-05-03 2003-08-08 Genodyssee Nouveaux polynucleotides et polypeptides de l'ifn alpha 5
WO2011092367A1 (es) 2010-02-01 2011-08-04 Digna Biotech,S.L. Procedimiento para la producción de interferón alfa 5
WO2012175700A1 (en) 2011-06-23 2012-12-27 Digna Biotech, S. L. Treatment of chronic hepatitis c with ifn-a5 combined with ifn-a2b in a cohort of patients
LT6164B (lt) 2013-10-15 2015-06-25 Uab Biotechnologinės Farmacijos Centras "Biotechpharma" Sulieti interferono-alfa 5 baltymai su kitu citokinu ir jų gamybos būdas

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4973479A (en) * 1982-01-15 1990-11-27 Cetus Corporation Interferon-α61
WO1992016622A1 (en) * 1991-03-12 1992-10-01 Biogen, Inc. Cd2-binding domain of lymphocyte function associated antigen 3
RU2052264C1 (ru) * 1993-07-19 1996-01-20 Товарищество с ограниченной ответственностью "Полисан" Лекарственное средство для лечения вирусных заболеваний у животных
JP4001379B2 (ja) * 1994-03-07 2007-10-31 インペリアル カレッジ オブ サイエンス，テクノロジー アンド メディシン ウィルス感染を治療する薬剤の調製におけるインターフェロンのサブタイプの使用
US6172046B1 (en) * 1997-09-21 2001-01-09 Schering Corporation Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DAVIS, G.L. et al. "Treatment of chronic hepatitis C with recombinant interferon alpha". THE NEW ENGLAND JOURNAL OF MEDICINE, 1989, Vol. 321, No 22, paginas 1501-1506. *
DI BISCEGLIE, A. et al. "Recombinant interferon alpha therapy for chronic hepatitis C". THE NEW ENGLAND JOURNAL OF MEDICINE, 1989, Vol. 321, paginas 1506-1510 *
FOSTER, G.R. et al. "Different relative activities of human cell-derived interferon-alpha subtypes: IFN-ALPHA8 has very high antiviral potency". JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, 1996, Vol. 16, No 12, paginas 1027-1033 *
MAUSS, S. et al. "Response to treatment of chronic hepatitis C with interferon alpha in patients infected with HIV-1 is associated with higher CD4+cell count". INFECTION, 1998, Vol. 26, No 1, paginas 16-19 *
SORIANO, V. et al. "Efficacy and safety of alpha-interferon treatment for chronic hepatitis C in HIV-infected patients". JOURNAL OF INFECTION, 1995, Vol. 31, paginas 9-13. *
SORIANO, V. et al. "Interferon alpha for the treatment of chronic hepatitis C in patients infected with human immunodeficiency virus". CLINICAL INFECTIOUS DISEASES, 1996, Vol. 23, paginas 585-591 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006032711A1 (es) * 2004-08-18 2006-03-30 Instituto Científico Y Tecnológico De Navarra S.A. Uso del factor de crecimiento semejante a la insulina tipo i y de interferón alfa en el tratamiento de una enfermedad hepática crónica, kit y composiciones que los comprenden
ES2303492A1 (es) * 2004-08-18 2008-08-01 Instituto Cientifico Y Tecnologico De Navarra S.A. Uso del factor de crecimiento semejante a la insulina tipo i y de interferon alfa en el tratamiento de una enfermedad hepatica cronica, kit y composiciones que los comprenden.

Also Published As

Publication number Publication date
DE69901099T2 (de) 2002-11-07
RU2209079C2 (ru) 2003-07-27
AU753463B2 (en) 2002-10-17
US7501392B2 (en) 2009-03-10
JP2002514606A (ja) 2002-05-21
EP1077068B9 (en) 2002-10-02
DE69901099T4 (de) 2003-03-13
PT1077068E (pt) 2002-07-31
DE69901099D1 (de) 2002-05-02
US20060188477A1 (en) 2006-08-24
SE1077068T5 (sv) 2003-03-04
ES2174604T3 (es) 2002-11-01
SE1077068T3 (sv) 2002-07-02
CA2335645A1 (en) 1999-11-18
CA2335645C (en) 2011-01-04
WO1999058143A9 (es) 2002-08-22
US6995133B1 (en) 2006-02-07
ES2138565B1 (es) 2000-08-16
DK1077068T3 (da) 2002-07-22
AU3711199A (en) 1999-11-29
ATE214941T1 (de) 2002-04-15
DK1077068T5 (da) 2002-10-14
CN1307482A (zh) 2001-08-08
CN1173738C (zh) 2004-11-03
EP1077068B1 (en) 2002-03-27
BR9911774A (pt) 2001-02-06
WO1999058143A1 (es) 1999-11-18
EP1077068A1 (en) 2001-02-21

Similar Documents

Publication Publication Date Title
ATE402957T1 (de) Analoge des menschlichen interferon-alpha mit niedriger toxizität
NZ503263A (en) Hepatitis C NS3 protease inhibitor peptides and peptide analogues
DE60324552D1 (en) Substituierte cycloalkyl p1' hepatitis c virus inhibitoren
PT728146E (pt) Peptideos de conotoxina
ITRM980061A0 (it) Procedimento per la produzione di peptidi com proprieta' inibitrici della sintesi ns3 del virus hcv peptidi cosi' ottenibili e peptidi
MX9703643A (es) Metodos para tratamiento de esclerosis multiple usando analogos de peptidos de proteina basica de mielina humana.
DE69518642D1 (de) Peptide zur induktion von immunantwort durch zytotoxischen t lymphocyten gegen das virus von hepatitis c
DE69922958D1 (de) Hcv hüllproteine partikel : verwendung für therapeutische impfung
BR9913406A (pt) Processo de tratamento de infecção causada por pelo menos um vìrus da famìlia flaviviridae e de doença associada com a citada infecção em um hospedeiro vivo possuindo a citada infecção
CO5700784A2 (es) Polipeptidos de virus de papiloma humano y composiciones in- munogenas
AU6020099A (en) Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein
AU3406595A (en) Nucleotide and amino acid sequences of the envelope 1 and core genes of hepatitis c virus
AU2197392A (en) Hepatitis C virus from C-100-3 and env/core regions
EP1501936A4 (en) PROTEIN FAMILY OF CYTOKINE
SE1077068T5 (sv) Anvaendning av interferon-alfa-5 vid behandling av virus-hepatopatier
MXPA02011969A (es) Metodos para el tratamiento de padecimientos virales con il-18 y combinaciones de il-18.
DE602004019141D1 (de) Isoleucyl-valyl-threonyl-asparaginyl-threonyl-threonin (ivtntt) enthaltende biologisch wirksame peptide
MXPA05007901A (es) Terapia de combinacion para hcv.
GB2356864B (en) Novel polypeptide
DK708488D0 (da) Faktor i praeparat
DE69827880D1 (de) Iga1-protease fragment als trägerpeptid
KR950000880A (ko) 한국형 씨(c)형 간염 바이러스의 일종인 케이에이치씨브이-엘2(khcv-l2)의 전체 뉴클레오티드서열 및 이로부터 유추된 아미노산 서열
EP1295943A4 (en) POLYPEPTIDES CAPABLE THE POWER TO STIMULATE NEUTROPHILES
ES2143918A1 (es) Peptidos inhibidores de la proteasa c y su utilizacion en la preparacion de composiciones utiles en las infecciones causadas por el virus de la hepatitis c.
GB0008504D0 (en) Novel polypeptide

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 20000101

Kind code of ref document: A1

Effective date: 20000101